NEWARK, Calif.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and therapeutic
conditions, today announced the expansion of its management team with
the appointments of Conor Gallagher, Ph.D., as Head of Medical Affairs,
Aesthetics, and Susanne Fors as Vice President, Regulatory Affairs. Both
appointments are effective immediately.
Dr. Gallagher joins the Clinical Development group and will oversee
Revance's Medical Affairs efforts in Aesthetics, reporting to Roman
Rubio, M.D., Sr. Vice President, Clinical Development. Dr. Gallagher
will join Daniel Snyder, Ph.D., current Head of Medical Affairs,
Therapeutics, in building a robust Medical Affairs leadership team. Ms.
Fors will oversee Revance's global regulatory affairs, including
regulatory operations, formation of clinical/regulatory strategies, and
regulatory submissions for aesthetics and therapeutics development
programs. She will report to Abhay Joshi, Ph.D., M.B.A., Chief Operating
"We are pleased to add these experienced global biopharma leaders to the
Revance team," said Dr. Joshi. "As we gear up for our regulatory filings
for RT002 in glabellar lines and potential commercialization of this
product in aesthetics, we value the oversight and expertise that both
Conor and Susanne will bring to their respective areas of responsibility
Dr. Gallagher joins Revance from Allergan where he spent the last 13
years, most recently as Executive Director, Global Lead Facial
Aesthetics, leading the company's efforts across multiple aesthetic
medicine products, including BOTOX® Cosmetic and the company's
line of dermal fillers. During his tenure at Allergan, he designed and
executed numerous Phase 4 drug, device and combination treatment
clinical trials and supported multiple new product or indication
launches in the U.S. and globally. Prior to Allergan, Dr. Gallagher
served as an Adjunct Professor of Anatomy at the University of Toronto.
He received his Ph.D. from the University of Toronto, and his Bachelor
of Physiotherapy from University College, Dublin.
Ms. Fors joins Revance from Genentech, where she held the position of
Global and US Regulatory Affairs Franchise Head for almost seven years.
She has led regulatory teams that covered development portfolios in
respiratory, inflammatory bowel disease, rheumatoid arthritis,
dermatology and rare immunology diseases. She also held leadership roles
in Regulatory Affairs in Europe as Head of EU/Rest of World (ROW)
Regulatory Affairs for UCB, a multinational biopharmaceutical company
headquartered in Brussels, Belgium. Earlier in her career, Ms. Fors led
many projects through approvals during her 14 years at AstraZeneca with
U.S., European and ROW regulatory agencies and has experience with FDA
Advisory Committees. She holds a Master of Science in Pharmacy from the
University of Uppsala, Sweden.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with plans to initiate
studies in upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. Revance has
developed a proprietary, stabilizing excipient peptide technology
designed to create novel, differentiated therapies. The company has a
comprehensive pipeline based upon its peptide technology, including
injectable and topical formulations of daxibotulinumtoxinA. More
information on Revance may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.
BOTOX is a registered trademark of Allergan, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180509006167/en/
Jeanie Herbert, 714-325-3584
Ami Bavishi, 212-213-0006
Mariann Caprino, 917-242-1087
Nadine Tosk, 504-453-8344
Source: Revance Therapeutics, Inc.
News Provided by Acquire Media